BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 31681270)

  • 1. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
    Carlsten M; Järås M
    Front Immunol; 2019; 10():2357. PubMed ID: 31681270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
    Front Immunol; 2021; 12():665541. PubMed ID: 33986753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
    Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review).
    Lee HR; Baek KH
    Oncol Rep; 2019 May; 41(5):2625-2635. PubMed ID: 30896812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
    Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
    Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
    [No Abstract]   [Full Text] [Related]  

  • 9. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
    Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
    Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cell-based immunotherapy for acute myeloid leukemia.
    Xu J; Niu T
    J Hematol Oncol; 2020 Dec; 13(1):167. PubMed ID: 33287858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
    Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploitation of natural killer cells for the treatment of acute leukemia.
    Handgretinger R; Lang P; André MC
    Blood; 2016 Jun; 127(26):3341-9. PubMed ID: 27207791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
    Arellano-Ballestero H; Sabry M; Lowdell MW
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cell immune escape in acute myeloid leukemia.
    Lion E; Willemen Y; Berneman ZN; Van Tendeloo VF; Smits EL
    Leukemia; 2012 Sep; 26(9):2019-26. PubMed ID: 22446501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
    Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
    Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of natural killer cells in the treatment of chronic myeloid leukemia.
    Silla LM; Whiteside TL; Ball ED
    J Hematother; 1995 Aug; 4(4):269-79. PubMed ID: 7489141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
    Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.